

Table SIII. Summary of curative radiation results for CD30⁺ primary cutaneous anaplastic large-cell lymphoma

Reference	Patients treated with curative radiation	Response to radiation	Disease control status
Bekkenk et al. (2)	38	N/A (99% CR rate for entire cohort receiving radiation, excision, or chemotherapy)	Median DFS: 23 months for entire cohort
Beljaards et al. (3)	9	N/A (97% CR rate for entire cohort receiving radiation, excision, or chemotherapy)	Four skin relapse at 2, 10, 12 and 30 months, whereas 1 lymph node relapse at 3 months
Shimizu et al. (4)	1	Complete remission	Disease-free for 5 months
Liu et al. ^a	7	Complete remission: 6/7 (85.7%)	2 recurrences
Yu et al. ^b	8	Complete remission: 8/8 (100%)	All patients in CR (1 patient died of unrelated causes)
Present study	9	Complete remission: 8/9 (88.9%), PR 1/9 (11.1%)	3-year DFS: 58.3%; 3-year OS: 70%

^a Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. *J Am Acad Dermatol* 2003; 49: 1049–1058.

^b Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. *Int J Radiat Oncol Biol Phys* 2008; 70: 1542–1545.

N/A: not available; PR: partial remission; DFS: disease-free survival; OS: overall survival.